Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs

Bibliography

• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar
• Recio-Mayoral A, Kaski JC, McMurray JJ, et al. Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc Drugs Ther 2007;21:459-65
   PubMed Web of Science ®Google Scholar
• Avilable from: http://csdd.tufts.edu
   Google Scholar
• Dumas M-E, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006;103:12511-6
   PubMed Web of Science ®Google Scholar
• Niculescu MD, Zeisel SH. Diet, methyl donors and DNA methylation: Interactions between dietary folate, methionine and choline. J Nutr 2002;132:2333-5
   PubMed Web of Science ®Google Scholar
• Bäckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science 2005;307:1915-20
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005;3:431-8
   PubMed Web of Science ®Google Scholar
• Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature 2006;444:1022-3
   PubMed Web of Science ®Google Scholar
• Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-23
   PubMed Web of Science ®Google Scholar
• van der Greef J, Stroobant P, Heijden Rvd. The role of analytical sciences in medical systems biology. Curr Opin Chem Biol 2004;8:559-65
   PubMed Web of Science ®Google Scholar
• Bollard ME, Stanley EG, Lindon JC, et al. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed 2005;18:143-62
   PubMed Web of Science ®Google Scholar
• Lindon JC, Holmes E, Nicholson JK. Metabonomics and its role in drug development and disease diagnosis. Expert Rev Mol Diag 2004;4:189-99
   PubMed Web of Science ®Google Scholar
• Oresic M, Vidal-Puig A, Hänninen V. Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev Mol Diagn 2006;6:575-85
   PubMed Web of Science ®Google Scholar
• Wenk MR. The emerging field of lipidomics. Nat Rev Drug Discov 2005;4:594-610
   PubMed Web of Science ®Google Scholar
• Kolak M, Westerbacka J, Velagapudi VR, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007;56:1960-8
   PubMed Web of Science ®Google Scholar
• Pietiläinen KH, Sysi-Aho M, Rissanen A, et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects: a monozygotic twin study. PLoS One 2007;2:e218
   PubMedGoogle Scholar
• Laaksonen R, Katajamaa M, Päivä H, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin induced changes in muscle. PLoS One 2006;1:e97
   PubMed Web of Science ®Google Scholar
• Schwudke D, Oegema J, Burton L, et al. Lipid profiling by multiple precursor and neutral loss scanning driven by the data-dependent acquisition. Anal Chem 2006;78:585-95
   PubMed Web of Science ®Google Scholar
• Ejsing CS, Duchoslav E, Sampaio J, et al. Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal Chem 2006;78:6202-14
   PubMed Web of Science ®Google Scholar
• Thomas MC, Mitchell TW, Harman DG, et al. Ozone-induced dissociation: elucidation of double bond position within mass-selected lipid ions. Anal Chem 2008;80:303-11
   PubMed Web of Science ®Google Scholar
• Thomas MC, Mitchell TW, Harman DG, et al. Elucidation of double bond position in unsaturated lipids by ozone electrospray ionization mass spectrometry. Anal Chem 2007;79:5013-22
   PubMed Web of Science ®Google Scholar
• Thomas MC, Mitchell TW, Blanksby SJ. Ozonolysis of phospholipid double bonds during electrospray ionization: a new tool for structure determination. J Am Chem Soc 2006;128:58-9
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Williams-Jones B, Glatt SJ, et al. Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol 2006;24:942-6
   PubMed Web of Science ®Google Scholar
• Batchelder K, Miller P. A change in the market: investing in diagnostics. Nat Biotechnol 2006;24:922-6
   PubMed Web of Science ®Google Scholar
• Holmes E, Tsang TM, Huang JT-J, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006;3:e327
   PubMedGoogle Scholar
• Kaddurah-Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007;12:934-45
   PubMed Web of Science ®Google Scholar
• Pietiläinen KH, Naukkarinen J, Rissanen A, et al. Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. PLoS Med 2008;5:e51
   PubMed Web of Science ®Google Scholar
• Lenz EM, Bright J, Wilson ID, et al. Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J Pharm Biomed Anal 2004;36:841-9
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Holmes E. Global systems biology and personalized healthcare solutions. Discov Med 2006;6:63-70
   PubMedGoogle Scholar
• Papassotiropoulos A, Wollmer MA, Tsolak IM, et al. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry 2005;66:940-7
   PubMed Web of Science ®Google Scholar
• Solberg LA, Strong JP. Risk factors and atherosclerotic lesions. A review of autopsy studies. Arteriosclerosis 1983;3:187-98
   PubMedGoogle Scholar
• Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-4
   PubMed Web of Science ®Google Scholar
• Altmann SW, Davis HR Jr, Yao X, et al. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochim Biophys Acta 2002;1580:77-93
   PubMed Web of Science ®Google Scholar
• Labonte ED, Howles PN, Granholm NA, et al. Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles. Biochim Biophys Acta 2007;1771:1132-9
   PubMed Web of Science ®Google Scholar
• van Bennekum A, Werder M, Thuahnai ST, et al. Class B scavenger receptor-mediated intestinal absorption of dietary beta-carotene and cholesterol. Biochemistry 2005;44:4517-25
   PubMed Web of Science ®Google Scholar
• Hui DY, Labonté ED, Howles PN. Development and Physiological Regulation of Intestinal Lipid Absorption. III. Intestinal transporters and cholesterol absorption. Am J Physiol Gastrointest Liver Physiol. 2008:294:G839-43
   PubMed Web of Science ®Google Scholar
• Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000;290:1771-5
   PubMed Web of Science ®Google Scholar
• Lee MH, Lu K, Hazard S, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001;27:79-83
   PubMed Web of Science ®Google Scholar
• Hussain MM, Fatma S, Pan X, Iqbal J. Intestinal lipoprotein assembly. Curr Opin Lipidol 2005;16:281-5
   PubMed Web of Science ®Google Scholar
• Havel RJ, Kane JP, Kashyap ML. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J Clin Invest 1973;52:32-8
   PubMed Web of Science ®Google Scholar
• Fielding CJ, Fielding PE. The activation of lipoprotein lipase by lipase co-protein (apo C-2). Expos Annu Biochim Med 1977;33:165-72
   PubMedGoogle Scholar
• Tall A. Plasma lipid transfer proteins. Annu Rev Biochem 1995;64:235-57
   PubMed Web of Science ®Google Scholar
• Herz J, Hamann U, Rogne S, et al. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988;7:4119-27
   PubMed Web of Science ®Google Scholar
• Bravo E, Napolitano M. Mechanisms involved in chylomicron remnant lipid uptake by macrophages. Biochem Soc Trans 2007;35:459-63
   PubMed Web of Science ®Google Scholar
• Botham KM, Moore EH, De Pascale C, Bejta F. The induction of macrophage foam cell formation by chylomicron remnants. Biochem Soc Trans 2007;35:454-8
   PubMed Web of Science ®Google Scholar
• Green PH, Glickman RM. Intestinal lipoprotein metabolism. J Lipid Res 1981;22:1153-73
   PubMed Web of Science ®Google Scholar
• Brunham LR, Kruit JK, Pape TD, et al. Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ Res 2006;99:672-4
   PubMed Web of Science ®Google Scholar
• Attie AD. ABCA1: at the nexus of cholesterol, HDL and atherosclerosis. Trends Biochem Sci 2007;32:172-9
   PubMed Web of Science ®Google Scholar
• Tang W, Ma Y, Jia L, et al. Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler Thromb Vasc Biol 2008;28:448-54
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993;34:1637-59
   PubMed Web of Science ®Google Scholar
• Zannis VI, Breslow JL, SanGiacomo TR, et al. Characterization of the major apolipoproteins secreted by two human hepatoma cell lines. Biochemistry 1981;20:7089-96
   PubMed Web of Science ®Google Scholar
• Dixon JL, Ginsberg HN. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res 1993;34:167-79
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Le NA, Short MP, et al. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest 1987;80:1692-7
   PubMed Web of Science ®Google Scholar
• Fuki IV, Preobrazhensky SN, Misharin A, et al. Effect of cell cholesterol content on apolipoprotein B secretion and LDL receptor activity in the human hepatoma cell line, HepG2. Biochim Biophys Acta 1989;1001:235-8
   PubMed Web of Science ®Google Scholar
• Adiels M, Taskinen MR, Boren J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 2008;8:60-4
   PubMed Web of Science ®Google Scholar
• Schaap FG, Rensen PC, Voshol PJ, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004;279:27941-7
   PubMed Web of Science ®Google Scholar
• Qiao L, Zou C, van der Westhuyzen DR, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL-triglyceride catabolism. Diabetes 2008: doi: 10.2337/db07-0435
   PubMedGoogle Scholar
• Nicoll A, Lewis B. Evaluation of the roles of lipoprotein lipase and hepatic lipase in lipoprotein metabolism: in vivo and in vitro studies in man. Eur J Clin Invest 1980;10:487-95
   PubMed Web of Science ®Google Scholar
• Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47
   PubMed Web of Science ®Google Scholar
• Seidah NG, Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med 2007;85:685-96
   PubMed Web of Science ®Google Scholar
• Phillips MC, Johnson WJ, Rothblat GH. Mechanisms and consequences of cellular cholesterol exchange and transfer. Biochim Biophys Acta 1987;906:223-76
   PubMed Web of Science ®Google Scholar
• Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 1968;9:155-67
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13-27
   PubMed Web of Science ®Google Scholar
• Patsch JR, Gotto AM Jr, Olivercrona T, Eisenberg S. Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro Proc Natl Acad Sci USA 1978;75:4519-23
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Navab M, Shih D, et al. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001;11:155-61
   PubMed Web of Science ®Google Scholar
• Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008;7:143-55
   PubMed Web of Science ®Google Scholar
• Miller NE, Hammett F, Saltissi S, et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J (Clin Res Ed)1981;282:1741-4
   PubMed Web of Science ®Google Scholar
• Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988;27:25-9
   PubMed Web of Science ®Google Scholar
• Brewer HB Jr, Remaley AT, Neufeld EB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004;24:1755-60
   PubMed Web of Science ®Google Scholar
• Wang N, Lan D, Gerbod-Giannone M, et al. ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux. J Biol Chem 2003;278:42906-12
   PubMed Web of Science ®Google Scholar
• Klucken J, Buchler C, Orso E, et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA 2000;97:817-22
   PubMed Web of Science ®Google Scholar
• Wang N, Lan D, Chen W, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004;101:9774-9
   PubMed Web of Science ®Google Scholar
• Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:1732-8
   PubMed Web of Science ®Google Scholar
• Wang M, Briggs MR. HDL: the metabolism, function, and therapeutic importance. Chem Rev 2004;104:119-37
   PubMed Web of Science ®Google Scholar
• Barrans A, Collet X, Barbaras R, et al. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem 1994;269:11572-7
   PubMed Web of Science ®Google Scholar
• Lie J, de Crom R, Jauhiainen M, et al. Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of pre beta-high-density lipoproteins. Biochem J 2001;360:379-85
   PubMed Web of Science ®Google Scholar
• Brundert M, Heeren J, Greten H, Rinninger F. Hepatic lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent from SR-BI. J Lipid Res 2003;44:1020-32
   PubMed Web of Science ®Google Scholar
• Martinez LO, Jacquet S, Esteve JP, et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75-9
   PubMed Web of Science ®Google Scholar
• Hammad SM, Barth JL, Knaak C, Argraves WS. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem 2000;275:12003-8
   PubMed Web of Science ®Google Scholar
• Hammad SM, Stefansson S, Twal WO, et al. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis. Proc Natl Acad Sci USA 1999;96:10158-63
   PubMed Web of Science ®Google Scholar
• Kozyraki R, Fyfe J, Kristiansen M, et al. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 1999;5:656-61
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45
   PubMed Web of Science ®Google Scholar
• Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-82
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7
   PubMed Web of Science ®Google Scholar
• Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007;48:1263-72
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9
   PubMed Web of Science ®Google Scholar
• Miller, G. E. and Stagnitti, M. N. Trends in Statin Use in the Civilian Noninstitutionalized Medicare Population, 1997 and 2002. Statistical Brief #97. September 2005. Agency for Healthcare Research and Quality, Rockville, Md. Available from: http://www.meps.ahrq.gov/mepsweb/data_files/publications/st97/stat97.pdf [Last accessed 23 April 2008]
   Google Scholar
• Walley T, Folino-Gallo P, Schwabe U, van Ganse E. Variations and increase in use of statins across Europe: data from administrative databases. BMJ 2004;328:385-6
   PubMed Web of Science ®Google Scholar
• Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157-63
   PubMed Web of Science ®Google Scholar
• Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007;14:99-108
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006;22:511-28
   PubMed Web of Science ®Google Scholar
• Toth PP, Davidson MH. Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:455-62
   PubMedGoogle Scholar
• Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008: doi: 10.1056/NEJMoa0800742
   Google Scholar
• Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37:161-5
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
   PubMed Web of Science ®Google Scholar
• Laaksonen R. On the mechanisms of statin-induced myopathy. Clin Pharmacol Ther 2006;79:529-31
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006;97:C44-51
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:C52-60C
   PubMed Web of Science ®Google Scholar
• Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80
   PubMed Web of Science ®Google Scholar
• Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 2004;24:1194-203
   PubMed Web of Science ®Google Scholar
• Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006;119:400-9
   PubMed Web of Science ®Google Scholar
• Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-62
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90
   PubMed Web of Science ®Google Scholar
• Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther 2005;85:459-65
   PubMed Web of Science ®Google Scholar
• Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5
   PubMed Web of Science ®Google Scholar
• Paiva H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005;78:60-8
   PubMed Web of Science ®Google Scholar